Background: Severe manifestations of COVID-19 include hypercoagulopathies and systemic endothelialitis. The underlying dynamics of vascular damage, and whether it is a direct consequence of endothelial infection or an indirect consequence of immune cell-mediated cytokine storms is unknown. This is in part because in vitro infection models are typically monocultures of epithelial cells or fail to recapitulate vascular physiology.
Methods: We establish a vascularised lung-on-chip infection model consisting of a co-culture of primary human alveolar epithelial (epithelial) cells and human lung microvascular endothelial (endothelial) cells, with the optional addition of CD14+ macrophages to the epithelial side. This model was used to study the dynamics of viral replication and host responses to a low dose infection of SARS-CoV-2 of the epithelial layer.
Findings: SARS-CoV-2 inoculation does not lead to a productive amplification of infectious virions. However, both genomic and antisense viral RNA can be found in endothelial cells within 1-day post infection (dpi) and persist upnto 3 dpi. This generates an NF-KB-mediated inflammatory response typified by IL-6 secretion and signalling coupled with a weak antiviral interferon response, even in the absence of immune cells. Endothelial inflammation leads to a progressive loss of barrier integrity, a subset of cells also shows a transient hyperplasic phenotype. Administration of Tocilizumab slows the loss of barrier integrity but does not reduce the occurrence of the latter.
Interpretation: Endothelial infection can occur through basolateral transmission from infected epithelial cells at the air-liquid interface. SARS-CoV-2 mediated inflammation occurs despite the lack of rapid viral replication and is transient in epithelial cells but persistent in endothelial cells. Infected endothelial cells might be a key source of circulating IL-6 in COVID-19 patients. Vascular damage occurs independently of immune-cell mediated cytokine storms, whose effect would only exacerbate the damage.
Funding: Core support from EPFL.